Related Experiment Video
Updated: Aug 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Noncompliance with programmed appointments in dyslipidemia patients in pharmacologic treatment]
F Piñeiro Chousa1, V F Gil Guillén, R Pastor López
1Departamento de Medicina, Universidad Miguel Hernández, Alicante.
Objectives:
To find the non-compliance of patients with Lipaemia with scheduled appointments, to define the profile of non-attending patients and to study the best way of identifying them.
Design:
Prospective study.
Setting:
Primary Care Centres in the province of Alicante.
Patients:
107 patients with Lipaemia from five General Medical clinics who received treatment with lipid-lowering drugs.
Measurements And Main Results:
Non-compliance was assessed by reviewing the appointment books. Non-compliant patients were defined as those who had not attended 80-100% of the appointments made in the six months since the beginning of the study. Non-compliance with appointments was 16.8% (CI: 9.7-23.9). In the profile study none of the variables analysed showed significant differences. Of the methods validated, level of knowledge had the highest sensitivity (88.9%: CI 81.9-94.1); and medical judgement the greatest specificity (86.5%: CI 79.5-92.5), with the coefficient for probability of low compliance 2.9 and best Kappa index 0.25.
Conclusions:
One out of every six patients with Lipaemia does not attend follow-up appointments. There is no profile of the non-compliant patient. Only medical judgement can be valid for suspecting non-compliance with scheduled appointments.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Atherosclerosis III: Management

